IMIHGOM and Cyto-Barr announce partnership
Leiden, June 28th, 2018. IMIHGOM B.V., a European Business Development & Licensing company, announced today that IMIHGOM and Cyto-Barr B.V. will collaborate on the out-licensing of Cyto-Barr’s programmes for treatment of Epstein-Barr Virus (EBV) associated diseases and cancers.
“We are delighted to partner with Cyto-Barr for the out-licensing of their innovative therapies targeting EBV-associated diseases. In particular, with EBV-associated cancers accounting for approximately 2% of all cancer-related deaths worldwide, there is a large unmet need for improved treatment options” said Mona Moghimi, Chief Executive Officer at IMIHGOM.
“We look forward to working with IMIHGOM to find industrial partners to implement our innovative methods, our lead reagents and expertise to find a cure for Nasopharyngeal cancer (NPC), Posttransplant Lymphoproliferative Disease (PTLD) and other EBV-linked cancer types” said Prof. Jaap Middeldorp, Chief Executive Officer at Cyto-Barr.
About IMIHGOM B.V.
Established in 2016 in Leiden, The Netherlands, IMIHGOM B.V. is a European Business Development & Licensing (BD&L) company with in-depth scientific and business experience and excellent track record. We work closely with our scientific and business advisory boards, comprised of internationally recognized experts in the fields of science, medicine and business development.
With a strong focus on oncology and neuroscience, IMIHGOM leverages this experience to support innovative companies operating in these spaces. For more information regarding IMIHGOM B.V. go to www.imihgom.com.
About Cyto-Barr B.V.
Cyto-Barr is a Dutch biotech company specialized in diagnostic testing and treatment of diseases, specifically in association with EBV or cytomegalovirus (CMV). Cyto-Barr are global leaders in development of biomarkers for EBV diagnostics, with more than 40 partners worldwide in diagnostics and therapies for EBV and CMV.
Cyto-Barr is developing innovative therapies targeting EBV in various EBV-associated cancer types and is involved in phase-I clinical studies for the treatment of nasopharyngeal carcinoma (NPC), which is endemic in certain parts of Asia and Indonesia. In the Netherlands a phase-I therapeutic study was recently started and in Indonesia we are preparing such clinical studies. We also actively pursue screening studies for the early identification of NPC, in order to improve treatment options. For more information, visit www.cyto-barr.com.
IMIHGOM Contact Cyto-Barr Contact
Mona Moghimi Jaap Middeldorp
Chief Executive Officer Chief Executive Officer
+31 (0)71 332-2120 firstname.lastname@example.org